Erasca, Inc. - Common Stock — Cash Flow (NASDAQ:ERAS) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -79.6 M-103.26 M-101.22 M-109.42 M-95.45 M -98.02 M Cash from investing activities -64.59 M-71.08 M-91.22 M-156.62 M100.42 M -173.92 M Cash from financing activities 439.4 M98.08 M1.29 M240.7 M1.1 M 248.34 M Free cash flow -79.6 M-103.26 M-101.22 M-109.42 M-95.58 M -98.08 M

News

Alger Mid Cap 40 ETF Q2 2026 Portfolio Review

Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'

Erasca: A Credible Rival To Revolution's Daroxonrasib, At A Cheaper Price Point (ERAS)

Tango Therapeutics Rides a New Precision Oncology Trend in 2026

Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?

TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts

Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite (TNGX)

TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results

Tango Therapeutics: 'Hold' On Combination Strategy Shift Of Vopimetostat (NASDAQ:TNGX)

Erasca, Inc. (ERAS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Erasca: "Hold" On Substantial RAS Targeting ERAS-0015 But With Two Key Risks (NASDAQ:ERAS)

Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results